Personalized Intraperitoneal Strategies in Gastric Cancer

  • Yang Yang
  • Nandie Wu
  • Jia Wei


Gastric cancer is the fourth most common cancer and the second leading cause of cancer deaths worldwide [1]. Except countries such as Korea and Japan that have routine national screening programs, most patients with gastric cancer are in advanced stages of the disease as early-stage gastric cancers are usually without symptoms and often develop advanced stage even after radical surgery. Despite developments in the surgical treatment of gastric cancer, there is a relatively high recurrence rate. Specifically, the 5-year overall survival rate for all diagnosed patients averages 24.5% in Europe [2] and 40–60% in Asia [3, 4]. The main reason for post-surgery treatment failure for gastric cancer is peritoneal dissemination, which is caused by the seeding of free cancer cells from the primary gastric cancer. This is one of the most common types of metastasis for gastric cancer. Gastric cancer patients with macroscopic peritoneal metastasis have very poor prognoses, with a median overall survival of 3–6 months [5, 6]. In this chapter, we try to describe the influence of peritoneal metastasis on survival in patients with gastric cancer, the possible mechanism of peritoneal metastasis, and individualized treatment strategy of gastric cancer patients at high risk for developing peritoneal metastasis.


Gastric Cancer Gastric Cancer Cell Gastric Cancer Patient Peritoneal Carcinomatosis Peritoneal Metastasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Leake PA, Cardoso R, Seevaratnam R, Lourenco L, Helyer L, Mahar A, Rowsell C, Coburn NG. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer. 2012;15(Suppl 1):S27–37.CrossRefPubMedGoogle Scholar
  2. 2.
    De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE—5-a population-based study. Lancet Oncol. 2014;15(1):23–34.CrossRefPubMedGoogle Scholar
  3. 3.
    Zeng WJ, Hu WQ, Wang LW, Yan SG, Li JD, Zhao HL, Peng CW, Yang GF, Li Y. Long term follow up and retrospective study on 533 gastric cancer cases. BMC Surg. 2014;14:29.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Matsuda T, Saika K. The 5-year relative survival rate of stomach cancer in the USA, Europe and Japan. Jpn J Clin Oncol. 2013;43(11):1157–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Yonemura Y, Elnemr A, Endou Y, Hirano M, Mizumoto A, Takao N, Ichinose M, Miura M, Li Y. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol. 2010;2(2):85–97.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Yonemura Y, Endou Y, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Miura M, Li Y. Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol. 2010;36(12):​1131–8.CrossRefPubMedGoogle Scholar
  7. 7.
    D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg. 2004;240(5):808–16.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chang JS, Lim JS, Noh SH, Hyung WJ, An JY, Lee YC, Rha SY, Lee CG, Koom WS. Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy. Radiother Oncol. 2012;104(3):367–73.CrossRefPubMedGoogle Scholar
  9. 9.
    Schwarz RE, Zagala-Nevarez K. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann Surg Oncol. 2002;9(4):394–400.CrossRefPubMedGoogle Scholar
  10. 10.
    Eom BW, Yoon H, Ryu KW, Lee JH, Cho SJ, Lee JY, Kim CG, Choi IJ, Lee JS, Kook MC, Park SR, Nam BH, Kim YW. Predictors of timing and patterns of recurrence after curative resection for gastric cancer. Dig Surg. 2010;27(6):481–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Jo JC, Ryu MH, Koo DH, Ryoo BY, Kim HJ, Kim TW, Choi KD, Lee GH, Jung HY, Yook JH, Oh ST, Kim BS, Kim JH, Kang YK. Serum CA 19-9 as a prognostic factor in patients with metastatic gastric cancer. Asia Pac J Clin Oncol. 2013;9(4):324–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Deng J, Liang H, Wang D, Sun D, Pan Y, Liu Y. Investigation of the recurrence patterns of gastric cancer following a curative resection. Surg Today. 2011;41(2):210–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87(2):236–42.CrossRefPubMedGoogle Scholar
  14. 14.
    Yoo C, Ryu MH, Park YS, Yoo MW, Park SR, Ryoo BY, Jang SJ, Yook JH, Kim BS, Kang YK. Intraoperatively assessed macroscopic serosal changes in patients with curatively resected advanced gastric cancer: clinical implications for prognosis and peritoneal recurrence. Ann Surg Oncol. 2015;22(9):2940–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Arita T, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Hiramoto H, Hamada J, Shoda K, Kawaguchi T, Hirajima S, Nagata H, Fujiwara H, Okamoto K, Otsuji E. Increase in peritoneal recurrence induced by intraoperative hemorrhage in gastrectomy. Ann Surg Oncol. 2015;22(3):758–64.CrossRefPubMedGoogle Scholar
  16. 16.
    Sakakura C, Hagiwara A, Nakanishi M, Shimomura K, Takagi T, Yasuoka R, Fujita Y, Abe T, Ichikawa Y, Takahashi S, Ishikawa T, Nishizuka I, Morita T, Shimada H, Okazaki Y, Hayashizaki Y, Yamagishi H. Differential gene expression profiles of gastric cancer cells established from primary tumour and malignant ascites. Br J Cancer. 2002;87(10):1153–61.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Hiraki M, Kitajima Y, Kai K, Nakamura J, Hashiguchi K, Noshiro H, Miyazaki K. Knockdown of hypoxia-inducible factor-1alpha accelerates peritoneal dissemination via the upregulation of MMP-1 expression in gastric cancer cell lines. Exp Ther Med. 2012;4(3):355–62.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Yonemura Y, Endou Y, Fujita H, Fushida S, Bandou E, Taniguchi K, Miwa K, Sugiyama K, Sasaki T. Role of MMP-7 in the formation of peritoneal dissemination in gastric cancer. Gastric Cancer. 2000;3(2):63–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Bai FH, Wang NJ, Wang J, Yang L, Zhang FM, Yin F, Liang J, Wu KC, Fan DM. Screening and identification of peritoneal metastasis-related genes of gastric adenocarcinoma using a cDNA microarray. Genet Mol Res. 2012;11(2):1682–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Jiang J, Liu W, Guo X, Zhang R, Zhi Q, Ji J, Zhang J, Chen X, Li J, Gu Q, Liu B, Zhu Z, Yu Y. IRX1 influences peritoneal spreading and metastasis via inhibiting BDKRB2-dependent neovascularization on gastric cancer. Oncogene. 2011;30(44):4498–508.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Shang FT, Hui LL, An XS, Zhang XC, Guo SG, Kui Z. ZnPPIX inhibits peritoneal metastasis of gastric cancer via its antiangiogenic activity. Biomed Pharmacother. 2015;71:240–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Graziosi L, Mencarelli A, Santorelli C, Renga B, Cipriani S, Cavazzoni E, Palladino G, Laufer S, Burnet M, Donini A, Fiorucci S. Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent model peritoneal metastasis. Eur J Pharmacol. 2012;674(2-3):143–52.CrossRefPubMedGoogle Scholar
  23. 23.
    Mencarelli A, Graziosi L, Renga B, Cipriani S, D’Amore C, Francisci D, Bruno A, Baldelli F, Donini A, Fiorucci S. CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination. Transl Oncol. 2013;6(6):784–93.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17(12):3077–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Matharu G, Tucker O, Alderson D. Systematic review of intraperitoneal chemotherapy for gastric cancer. Br J Surg. 2011;98(9):1225–35.CrossRefPubMedGoogle Scholar
  26. 26.
    Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, Morris DL. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14(10):2702–13.CrossRefPubMedGoogle Scholar
  27. 27.
    Kojima N, Kunieda K, Matsui K, Kato H, Saji S. Evaluation of carcinoembryonic antigen mRNA in living, necrotic, and apoptotic gastric cancer cells by reverse transcriptase-polymerase chain reaction. Surg Today. 2003;33(11):839–46.CrossRefPubMedGoogle Scholar
  28. 28.
    To EM, Chan WY, Chow C, Ng EK, Chung SC. Gastric cancer cell detection in peritoneal washing: cytology versus RT-PCR for CEA transcripts. Diagn Mol Pathol. 2003;12(2):88–95.CrossRefPubMedGoogle Scholar
  29. 29.
    De Andrade JP, Mezhir JJ. The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review. J Surg Oncol. 2014;110(3):​291–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Bentrem D, Wilton A, Mazumdar M, Brennan M, Coit D. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol. 2005;12​(5):347–53.CrossRefPubMedGoogle Scholar
  31. 31.
    Kodera Y, Nakanishi H, Ito S, Mochizuki Y, Ohashi N, Yamamura Y, Fujiwara M, Koike M, Tatematsu M, Nakao A. Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: analysis of real time reverse transcriptase-polymerase chain reaction after 5 years of followup. J Am Coll Surg. 2006;202(2):​231–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Kang KK, Hur H, Byun CS, Kim YB, Han SU, Cho YK. Conventional cytology is not beneficial for predicting peritoneal recurrence after curative surgery for gastric cancer: results of a prospective clinical study. J Gastric Cancer. 2014;14(1):23–31.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Fujiwara Y, Doki Y, Taniguchi H, Sohma I, Takiguchi S, Miyata H, Yamasaki M, Monden M. Genetic detection of free cancer cells in the peritoneal cavity of the patient with gastric cancer: present status and future perspectives. Gastric Cancer. 2007;10(4):197–204.CrossRefPubMedGoogle Scholar
  34. 34.
    Yabusaki N, Yamada S, Murai T, Kanda M, Kobayashi D, Tanaka C, Fujii T, Nakayama G, Sugimoto H, Koike M, Nomoto S, Fujiwara M, Kodera Y. Clinical significance of zinc-finger E-box binding homeobox 1 mRNA levels in peritoneal washing for gastric cancer. Mol Clin Oncol. 2015;3(2):435–41.PubMedGoogle Scholar
  35. 35.
    Jeon CH, Kim IH, Chae HD. Prognostic value of genetic detection using CEA and MAGE in peritoneal washes with gastric carcinoma after curative resection: result of a 3-year follow-up. Medicine (Baltimore). 2014;93(11):e83.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Kowalewska M, Chechlinska M, Nowak R. Carcinoembryonic antigen and cytokeratin 20 in peritoneal cells of cancer patients: are we aware of what we are detecting by mRNA examination? Br J Cancer. 2008;98(2):512–3. author reply 4CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Kitayama J, Emoto S, Yamaguchi H, Ishigami H, Onoyama H, Yamashita H, Seto Y, Matsuzaki K, Watanabe T. Flow cytometric quantification of intraperitoneal free tumor cells is a useful biomarker in gastric cancer patients with peritoneal metastasis. Ann Surg Oncol. 2015;22(7):2336–42.CrossRefPubMedGoogle Scholar
  38. 38.
    Yu JL, Lv P, Han J, Zhu X, Hong LL, Zhu WY, Wang XB, Wu YC, Li P, Ling ZQ. Methylated TIMP-3 DNA in body fluids is an independent prognostic factor for gastric cancer. Arch Pathol Lab Med. 2014;138(11):​1466–73.CrossRefPubMedGoogle Scholar
  39. 39.
    Roviello F, Marrelli D, Neri A, Cerretani D, de Manzoni G, Pedrazzani C, Cioppa T, Nastri G, Giorgi G, Pinto E. Treatment of peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP): postoperative outcome and risk factors for morbidity. World J Surg. 2006;30(11):2033–40. discussion 41–2.CrossRefPubMedGoogle Scholar
  40. 40.
    Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer. 1999;85(3):529–34.CrossRefPubMedGoogle Scholar
  41. 41.
    Montori G, Coccolini F, Ceresoli M, Catena F, Colaianni N, Poletti E, Ansaloni L. The treatment of peritoneal carcinomatosis in advanced gastric cancer: state of the art. Int J Surg Oncol. 2014;2014:912418.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Di Vita M, Cappellani A, Piccolo G, Zanghi A, Cavallaro A, Bertola G, Bolognese A, Facchini G, D'Aniello C, Di Francia R, Cardi F, Berretta M. The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer: between lights and shadows. Anticancer Drugs. 2015;26(2):123–38.CrossRefPubMedGoogle Scholar
  43. 43.
    Desai AD, Hawksworth GM. Cryopreservation of rat hepatocytes with high attachment efficiency and mixed function oxidase activity post thawing. Biochem Soc Trans. 1990;18(6):1214.CrossRefPubMedGoogle Scholar
  44. 44.
    Brucher BL, Piso P, Verwaal V, Esquivel J, Derraco M, Yonemura Y, Gonzalez-Moreno S, Pelz J, Konigsrainer A, Strohlein M, Levine EA, Morris D, Bartlett D, Glehen O, Garofalo A, Nissan A. Peritoneal carcinomatosis: cytoreductive surgery and HIPEC—overview and basics. Cancer Invest. 2012;30(3):209–24.CrossRefPubMedGoogle Scholar
  45. 45.
    Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R, Riess H. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002;43(1):33–56.CrossRefPubMedGoogle Scholar
  46. 46.
    Eppink B, Krawczyk PM, Stap J, Kanaar R. Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies. Int J Hyperthermia. 2012;28(6):509–17.CrossRefPubMedGoogle Scholar
  47. 47.
    Spratt JS, Adcock RA, Sherrill W, Travathen S. Hyperthermic peritoneal perfusion system in canines. Cancer Res. 1980;40(2):253–5.PubMedGoogle Scholar
  48. 48.
    Sugarbaker PH, Stuart OA, Yoo D. Strategies for management of the peritoneal surface component of cancer: cytoreductive surgery plus perioperative intraperitoneal chemotherapy. J Oncol Pharm Pract. 2005;11(3):111–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Graziosi L, Marino E, Donini A. Role of CRS plus HIPEC in gastric cancer peritoneal carcinomatosis. J Surg Oncol. 2015;111(2):248.CrossRefPubMedGoogle Scholar
  50. 50.
    Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Fujimoto S, Takahashi M, Kobayashi K, Kure M, Mutou T, Masaoka H, Ohkubo H. Relation between clinical and histologic outcome of intraperitoneal hyperthermic perfusion for patients with gastric cancer and peritoneal metastasis. Oncology. 1993;50(5):338–43.CrossRefPubMedGoogle Scholar
  52. 52.
    Sha H, Zou Z, Xin K, Bian X, Cai X, Lu W, Chen J, Chen G, Huang L, Blair AM, Cao P, Liu B. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy. J Control Release. 2015;200:188–200.CrossRefPubMedGoogle Scholar
  53. 53.
    Glockzin G, Piso P. Current status and future directions in gastric cancer with peritoneal dissemination. Surg Oncol Clin N Am. 2012;21(4):625–33.CrossRefPubMedGoogle Scholar
  54. 54.
    Cabalag CS, Chan ST, Kaneko Y, Duong CP. A systematic review and meta-analysis of gastric cancer treatment in patients with positive peritoneal cytology. Gastric Cancer. 2015;18(1):11–22.CrossRefPubMedGoogle Scholar
  55. 55.
    Shitara K, Mizota A, Matsuo K, Sato Y, Kondo C, Takahari D, Ura T, Tajika M, Muro K. Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis. Gastric Cancer. 2013;16(1):48–55.CrossRefPubMedGoogle Scholar
  56. 56.
    Oshima T, Yamada R, Hatori S, Kunisaki C, Imada T. Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer. Oncol Rep. 2006;16(2):361–6.PubMedGoogle Scholar
  57. 57.
    Peng YF, Imano M, Itoh T, Satoh T, Chiba Y, Imamoto H, Tsubaki M, Nishida S, Yasuda T, Furukawa H. A phase II trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential S-1 plus intravenous paclitaxel for serosa-positive gastric cancer. J Surg Oncol. 2015;111(8):1041–6.CrossRefPubMedGoogle Scholar
  58. 58.
    Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol. 1994;12(5):970–4.CrossRefPubMedGoogle Scholar
  59. 59.
    Morgan Jr RJ, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res. 2003;9(16 Pt 1):5896–901.PubMedGoogle Scholar
  60. 60.
    Tsujimoto H, Hagiwara A, Shimotsuma M, Sakakura C, Osaki K, Sasaki S, Ohyama T, Ohgaki M, Imanishi T, Yamazaki J, Takahashi T. Role of milky spots as selective implantation sites for malignant cells in peritoneal dissemination in mice. J Cancer Res Clin Oncol. 1996;122(10):590–5.CrossRefPubMedGoogle Scholar
  61. 61.
    Kitayama J, Ishigami H, Yamaguchi H, Yamashita H, Emoto S, Kaisaki S. S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis. Gastrointest Cancer Res. 2012;5(3 Suppl 1):S10–3.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, Oyama K, Sudo Y, Watanabe Y, Fujimura T. Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2013;71(5):1265–72.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Mori M, Doki Y. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol. 2012;105(1):38–42.CrossRefPubMedGoogle Scholar
  64. 64.
    Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 2003;4(5):277–83.CrossRefPubMedGoogle Scholar
  65. 65.
    Turcotte S, Sideris L, Younan R, Drolet P, Dube P. Pharmacokinetics of intraperitoneal irinotecan in a pig model. J Surg Oncol. 2010;101(7):637–42.CrossRefPubMedGoogle Scholar
  66. 66.
    Chambers SK, Chow HH, Janicek MF, Cragun JM, Hatch KD, Cui H, Laughren C, Clouser MC, Cohen JL, Wright HM, Abu Shahin N, Alberts DS. Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer. Clin Cancer Res. 2012;18(9):2668–78.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Bijelic L, Stuart OA, Sugarbaker P. Adjuvant bidirectional chemotherapy with intraperitoneal pemetrexed combined with intravenous Cisplatin for diffuse malignant peritoneal mesothelioma. Gastroenterol Res Pract. 2012;2012:890450.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer. 2010;127(9):2209–21.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Strohlein MA, Lordick F, Ruttinger D, Grutzner KU, Schemanski OC, Jager M, Lindhofer H, Hennig M, Jauch KW, Peschel C, Heiss MM. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Onkologie. 2011;34(3):101–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2017

Authors and Affiliations

  • Yang Yang
    • 1
  • Nandie Wu
    • 1
  • Jia Wei
    • 1
  1. 1.The Comprehensive Cancer Centre of Drum Tower HospitalMedical School of Nanjing University and Clinical Cancer Institute of Nanjing UniversityNanjingChina

Personalised recommendations